259 related articles for article (PubMed ID: 26524186)
1. Expression of CD164 on Malignant T cells in Sézary Syndrome.
Guenova E; Ignatova D; Chang YT; Contassot E; Mehra T; Saulite I; Navarini AA; Mitev V; Dummer R; Kazakov DV; French LE; Hoetzenecker W; Cozzio A
Acta Derm Venereol; 2016 May; 96(4):464-7. PubMed ID: 26524186
[TBL] [Abstract][Full Text] [Related]
2. The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells.
Bernengo MG; Novelli M; Quaglino P; Lisa F; De Matteis A; Savoia P; Cappello N; Fierro MT
Br J Dermatol; 2001 Jan; 144(1):125-35. PubMed ID: 11167693
[TBL] [Abstract][Full Text] [Related]
3. CD164 identifies CD4
Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
[TBL] [Abstract][Full Text] [Related]
4. The role of 9-O-acetylated ganglioside D3 (CD60) and {alpha}4{beta}1 (CD49d) expression in predicting the survival of patients with Sezary syndrome.
Scala E; Abeni D; Pomponi D; Narducci MG; Lombardo GA; Mari A; Frontani M; Picchio MC; Pilla MA; Caprini E; Russo G
Haematologica; 2010 Nov; 95(11):1905-12. PubMed ID: 20663947
[TBL] [Abstract][Full Text] [Related]
5. CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in Sézary syndrome patients.
Wysocka M; Kossenkov AV; Benoit BM; Troxel AB; Singer E; Schaffer A; Kim B; Dentchev T; Nagata S; Ise T; Showe LC; Rook AH
J Invest Dermatol; 2014 Jan; 134(1):229-236. PubMed ID: 23792457
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotyping of Sézary cells.
Russell-Jones R
Br J Dermatol; 2001 Jan; 144(1):2-3. PubMed ID: 11167675
[No Abstract] [Full Text] [Related]
7. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.
Feng B; Jorgensen JL; Jones D; Chen SS; Hu Y; Medeiros LJ; Wang SA
Mod Pathol; 2010 Feb; 23(2):284-95. PubMed ID: 19935642
[TBL] [Abstract][Full Text] [Related]
8. Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sézary's syndrome.
Lima M; Almeida J; dos Anjos Teixeira M; Queiros ML; Santos AH; Fonseca S; Balanzategui A; Justica B; Orfao A
Haematologica; 2003 Aug; 88(8):874-87. PubMed ID: 12935975
[TBL] [Abstract][Full Text] [Related]
9. Blood flow cytometry in Sézary syndrome: new insights on prognostic relevance and immunophenotypic changes during follow-up.
Novelli M; Fava P; Sarda C; Ponti R; Osella-Abate S; Savoia P; Bergallo M; Lisa F; Fierro MT; Quaglino P
Am J Clin Pathol; 2015 Jan; 143(1):57-69. PubMed ID: 25511143
[TBL] [Abstract][Full Text] [Related]
10. Single TCR-Vβ2 evaluation discloses the circulating T cell clone in Sezary syndrome: one family fits all!
Scala E; Abeni D; Pomponi D; Russo N; Russo G; Narducci MG
Arch Dermatol Res; 2015 Aug; 307(6):487-93. PubMed ID: 25733488
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome.
Nagler AR; Samimi S; Schaffer A; Vittorio CC; Kim EJ; Rook AH
J Am Acad Dermatol; 2012 Mar; 66(3):503-8. PubMed ID: 22005074
[TBL] [Abstract][Full Text] [Related]
12. Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome.
Introcaso CE; Hess SD; Kamoun M; Ubriani R; Gelfand JM; Rook AH
J Am Acad Dermatol; 2005 Sep; 53(3):428-34. PubMed ID: 16112348
[TBL] [Abstract][Full Text] [Related]
13. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome.
Sokolowska-Wojdylo M; Wenzel J; Gaffal E; Steitz J; Roszkiewicz J; Bieber T; Tüting T
Clin Exp Dermatol; 2005 Nov; 30(6):702-6. PubMed ID: 16197392
[TBL] [Abstract][Full Text] [Related]
14. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.
Lyapichev KA; Bah I; Huen A; Duvic M; Routbort MJ; Wang W; Jorgensen JL; Medeiros LJ; Vega F; Craig FE; Wang SA
Cytometry B Clin Cytom; 2021 Mar; 100(2):183-191. PubMed ID: 32667737
[TBL] [Abstract][Full Text] [Related]
15. Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sézary syndrome).
Vonderheid EC; Bigler RD; Kotecha A; Boselli CM; Lessin SR; Bernengo MG; Polansky M
J Invest Dermatol; 2001 Sep; 117(3):654-62. PubMed ID: 11564173
[TBL] [Abstract][Full Text] [Related]
16. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome.
Bouwhuis SA; Markovic SN; McEvoy MT; Pittelkow MR
Mayo Clin Proc; 2002 Feb; 77(2):197-200. PubMed ID: 11838656
[TBL] [Abstract][Full Text] [Related]
17. The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers.
Klemke CD; Brade J; Weckesser S; Sachse MM; Booken N; Neumaier M; Goerdt S; Nebe TC
Br J Dermatol; 2008 Sep; 159(4):871-80. PubMed ID: 18652582
[TBL] [Abstract][Full Text] [Related]
18. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sézary syndrome.
Fierro MT; Comessatti A; Quaglino P; Ortoncelli M; Osella Abate S; Ponti R; Novelli M; Bernengo MG
Dermatology; 2006; 213(4):284-92. PubMed ID: 17135733
[TBL] [Abstract][Full Text] [Related]
19. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
Durgin JS; Jariwala NN; Wysocka M; Zhang KK; Maity A; Benoit B; Plastaras JP; Lewis DJ; Rosenthal JM; Teague JE; Berg S; Del Guzzo C; Kim EJ; Vittorio C; Haun PL; Samimi SS; Villasenor-Park J; Inverso J; Clark RA; Rook AH
JAMA Dermatol; 2021 Jan; 157(1):90-95. PubMed ID: 33112366
[TBL] [Abstract][Full Text] [Related]
20. Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7.
Sokolowska-Wojdylo M; Wenzel J; Gaffal E; Lenz J; Speuser P; Erdmann S; Abuzahra F; Bowman E; Roszkiewicz J; Bieber T; Tüting T
Br J Dermatol; 2005 Feb; 152(2):258-64. PubMed ID: 15727636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
